Cisplatin-enriching cancer stem cells confer multidrug resistance in non-small cell lung cancer via enhancing TRIB1/HDAC activity.
about
Activation of an AKT/FOXM1/STMN1 pathway drives resistance to tyrosine kinase inhibitors in lung cancer.Acetylation and deacetylation in cancer stem-like cells.Long non-coding RNA LINC00261 sensitizes human colon cancer cells to cisplatin therapy.Drug Resistance Driven by Cancer Stem Cells and Their Niche.Hyper-acetylation contributes to the sensitivity of chemo-resistant prostate cancer cells to histone deacetylase inhibitor Trichostatin A.EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer.lincROR influences the stemness and crizotinib resistance in EML–ALK+ non-small-cell lung cancer cells.Redox-responsive self-assembly PEG nanoparticle enhanced triptolide for efficient antitumor treatmentThe Antihelminthic Niclosamide Inhibits Cancer Stemness, Extracellular Matrix Remodeling, and Metastasis through Dysregulation of the Nuclear β-catenin/c-Myc axis in OSCC
P2860
Q38603815-A993F782-5206-4E82-818F-8B2BE44CFC7CQ47106297-0BA756A3-3F05-4A90-9F93-1CC5CC5CED01Q47115706-73EDAB08-AD0A-4FBD-92BE-52494662A467Q47169621-C179540D-3B4C-42F0-90F5-A28F525214F5Q48254532-EFA5BA29-F0DE-407E-8926-2A267F354371Q48325256-EBA114C1-4FE1-4D36-A9F0-77323EB2DC46Q55291940-1E363D19-425F-45D8-90A7-C8AF7DF01923Q58699598-FFFDB215-2ADC-46A6-9910-9FFB8EFEED49Q58708393-6D140BA4-4AF6-475E-A231-1A0EEBE4126F
P2860
Cisplatin-enriching cancer stem cells confer multidrug resistance in non-small cell lung cancer via enhancing TRIB1/HDAC activity.
description
2017 nî lūn-bûn
@nan
2017 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2017 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
name
Cisplatin-enriching cancer ste ...... enhancing TRIB1/HDAC activity.
@ast
Cisplatin-enriching cancer ste ...... enhancing TRIB1/HDAC activity.
@en
type
label
Cisplatin-enriching cancer ste ...... enhancing TRIB1/HDAC activity.
@ast
Cisplatin-enriching cancer ste ...... enhancing TRIB1/HDAC activity.
@en
prefLabel
Cisplatin-enriching cancer ste ...... enhancing TRIB1/HDAC activity.
@ast
Cisplatin-enriching cancer ste ...... enhancing TRIB1/HDAC activity.
@en
P2093
P2860
P356
P1476
Cisplatin-enriching cancer ste ...... enhancing TRIB1/HDAC activity.
@en
P2093
Huiping Chen
Jingyu Yang
Jingyuan Zhang
Junli Chen
Lihui Wang
Wenlong Zhou
Xiangzhong Yuan
P2860
P2888
P356
10.1038/CDDIS.2016.409
P577
2017-04-13T00:00:00Z
P6179
1084812428